Genprex, Inc.

162 articles about Genprex, Inc.

• Genprex Announces $7.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

  7/19/2023

  Genprex, Inc.  today announced that it has entered into definitive agreements with healthcare-focused institutional investors for the sale and issuance of 7,425,744 shares of the Company's common stock and warrants to purchase up to 7,425,744 shares of common stock at a combined offering price of $1.01 per share.

• Genprex Signs Exclusive License to Additional Diabetes Technology with the University of Pittsburgh - July 18, 2023

  7/18/2023

  Genprex, Inc. today announced it has entered into an exclusive license agreement with the University of Pittsburgh.

• Genprex Granted Chinese Patent for REQORSA® Immunogene Therapy in Combination with PD-1 Antibodies to Treat Cancers

  7/5/2023

  Genprex, Inc. today announced that the China National Intellectual Property Administration has granted Genprex China Patent No: 201780076886.X.

• Genprex Receives U.S. FDA Fast Track Designation for REQORSA® Immunogene Therapy in Combination with Tecentriq® for the Treatment of Small Cell Lung Cancer

  6/28/2023

  Genprex, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) for the Company's lead drug candidate, REQORSA® Immunogene Therapy, in combination with Genentech, Inc.'s Tecentriq® in patients with extensive-stage small cell lung cancer (ES-SCLC) who did not develop tumor progression after receiving Tecentriq and chemotherapy as initial standard treatment.

• Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Expansion Portion of Acclaim-1 Clinical Trial of REQORSA® in Combination with Tagrisso® in Advanced Non-Small Cell Lung Cancer

  5/30/2023

  Genprex, Inc. today announced that it has completed the Phase 1 portion of the Acclaim-1 Phase 1/2 clinical trial of REQORSA® in combination with Tagrisso® (osimertinib) to treat late-stage non-small cell lung cancer (NSCLC), and the Safety Review Committee (SRC) has approved continuation to the Phase 2 expansion portion of the trial.

• Genprex Publishes Positive Clinical Data from Phase 1 Portion of Acclaim-1 Clinical Trial Evaluating REQORSA® Immunogene Therapy in Non-Small Cell Lung Cancer at the 2023 ASCO Annual Meeting

  5/25/2023

  Genprex, Inc. announced that positive data from the Phase 1 portion of its Acclaim-1 clinical trial evaluating REQORSA® Immunogene Therapy in combination with Tagrisso® in late-stage non-small cell lung cancer were published in an abstract at the 2023 American Society of Clinical Oncology Annual Meeting, taking place June 2-6, 2023 in Chicago, IL and online.

• Genprex Unveils New Video Featuring Chief Medical Officer Discussing Positive Preclinical Data With NPRL2 Gene Therapy Utilizing Non-Viral ONCOPREX® Nanoparticle Delivery System

  5/23/2023

  Genprex, Inc. today released a new video where the company's Chief Medical Officer, Mark Berger, MD, discusses the recently presented positive preclinical data for the NPRL2 gene by Genprex's research collaborators.

• Genprex to Participate and Present at Upcoming May Industry and Investor Conferences

  5/8/2023

  Genprex, Inc. today announced the Company's participation in the following upcoming industry and investor conferences to be held in May 2023.

• Cancer And Diabetes Remain Among The Deadliest And Most Debilitating Diseases - Is Gene Therapy The Solution? One Company, Genprex, Inc. (NASDAQ: GNPX), Thinks So

  4/19/2023

  On their own, cancer or diabetes can be debilitating and deadly. The two are common diseases with tremendous impact on health worldwide.

• Independent Researchers Find That TUSC2, the Gene Delivered by Genprex's REQORSA®, Functions as a Novel Tumor Suppressor for Glioblastoma

  4/18/2023

  Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX) today announced that independent researchers recently presented preclinical data on the tumor suppressor gene, TUSC2, reporting that it functions as a novel tumor suppressor for glioblastoma.

• Genprex CEO Commends FDA's Initiative to Accelerate Approval Process for Gene Therapies

  3/23/2023

  Rodney Varner , CEO of Genprex, Inc. today commended The U.S. Food and Drug Administration's (FDA) initiative that aims to expedite the development of gene therapies for patients with rare diseases.

• Genprex to Present at Bioprocessing Summit Conference

  3/13/2023

  Genprex, Inc. today announced the Company's Chief Manufacturing and Technology Officer, Hemant Kumar, Ph.D., will participate in the upcoming Bioprocessing Summit Europe Conference taking place March 14-16, 2023 in Barcelona, Spain.

• 

  CRISPR/ViaCyte and Genprex Vie for First Diabetes Gene Therapy

  3/13/2023

  Partners CRISPR and ViaCyte (Vertex), and Genprex are pioneers in the quest to develop a gene therapy for Type 1 diabetes.

• Genprex to Participate in March Investor and Industry Conferences

  3/8/2023

  Genprex, Inc. today announced the Company's participation in the following upcoming investor and industry conferences to be held in March 2023.

• Genprex, Inc. Announces $4 Million Registered Direct Offering With a Single, Healthcare-Focused Institutional Investor

  2/27/2023

  Genprex, Inc. announced it has entered into a securities purchase agreement with a single, healthcare-focused institutional investor for the purchase and sale of 3,809,524 shares of its common stock together with warrants to purchase up to 3,809,524 shares of common stock at a combined purchase price of $1.05 per share and accompanying warrant, pursuant to a registered direct offering.

• Genprex Announces Groundbreaking Data from Non-Human Primate Study Evaluating Novel Gene Therapy to Treat Type 1 Diabetes

  2/23/2023

  Genprex, today announced that data highlighting the potential of Genprex's gene therapy for Type 1 diabetes is being presented by its research collaborators at the University of Pittsburgh (Pitt) at the 16th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2023) taking place February 22-25, 2023 in Berlin, Germany. 

• Genprex Signs Exclusive License to Additional Diabetes Technology with the University of Pittsburgh

  1/5/2023

  Genprex, Inc. announced it has entered into an exclusive license agreement with the University of Pittsburgh, granting Genprex a worldwide, exclusive license to a patent application and related technology and a worldwide, non-exclusive license to use certain related know-how, all related to gene therapy for Type 2 diabetes using the genes of the Pdx1 and MafA transcription factors.

• Genprex Announces Selection of Preclinical Data for Oral Presentation at 16th International Conference on Advanced Technologies & Treatments for Diabetes

  1/4/2023

  Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX) today announced that its research collaborators at the University of Pittsburgh will present preclinical data highlighting the therapeutic potential of Genprex's gene therapy for Type 1 diabetes at the 16th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2023) being held February 22-25 in Berlin, Germany and online.

• Genprex Strengthens Diabetes Gene Therapy Program with License of Additional Technology from University of Pittsburgh

  12/15/2022

  Genprex, Inc. today announced it has entered into an exclusive license agreement (the Agreement) with the University of Pittsburgh, granting Genprex a worldwide, exclusive license to certain patent applications and related technology and a worldwide, non-exclusive license to use certain related know-how, all related to modulating autoimmunity in Type 1 diabetes by using gene therapy.

• Genprex Receives Safety Review Committee Approval to Proceed to Final Cohort in Acclaim-1 Phase 1 Dose Escalation Trial of REQORSA® in Combination with Tagrisso® in Advanced Non-Small Cell Lung Cancer

  12/14/2022

  Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX) today announced that the Safety Review Committee (SRC) has approved continuation to the third and final cohort in the dose escalation Phase 1 portion of the Acclaim-1 Phase 1/2 clinical trial of REQORSA® in combination with Tagrisso® (osimertinib) to treat late-stage non-small cell lung cancer (NSCLC).